← TrialMatch
HomeTrials

A Study to Prevent Infantile Spasms Relapse

After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, and effective in red

Condition(s)Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
StatusRecruiting
PhasePhase 2
Study typeInterventional
SummaryAfter initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, and effective in reducing the risk of relapse.
Who can participateInclusion Criteria: 1. Age 2 to 18 months, inclusive 2. Clinical diagnosis of infantile spasms syndrome, with EEG-confirmed complete response to standard treatment (prednisolone, ACTH, and/or vigabatrin) Exclusion Criteria: 1. Presence of clinically significant hypertension, infection, or any other diagnosis which poses unreasonable risk in the setting of extended corticosteroid therapy, in the view of the study physician 2. Exposure to any artisanal cannabinoid product within 14 days of screening 3. Ongoing therapy with the ketogenic diet 4. Implantation of a vagal nerve stimulator within 3 months of screening, or any change in stimulation parameters within 1 month of screening 5. Treatment of IESS via epilepsy surgery
Ages2 Months to 18 Months
SexAll
Lead sponsorUniversity of California, Los Angeles
LocationsLos Angeles, California, United States
Start date2025-05-05
NCT IDNCT06819670
Official listinghttps://clinicaltrials.gov/study/NCT06819670

🔍 Search all trials →